MarginsXMarginsX
Home › Markets › Health Care › VNDA

Vanda Pharmaceuticals Inc. (VNDA)

VNDA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.81
-4.51% on the day
Market cap
$230.4M
Micro cap
Revenue · 2025
$216.1M
+8.7% on 2024
Net income · 2025
-$220.5M
-102.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/0001628280-26-007460-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerVNDA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2006
SEC CIK0001347178
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$216.1M
Net income-$220.5M
Operating income-$151.2M
Net margin-102.0%
Operating margin-70.0%
Revenue growth+8.7%
Cash$84.9M
Total assets$488.9M
P/E (computed)Net income was not positive
P/S (computed)1.1×

Warning signs

Cash runway
5.3 months
$61.9M cash at September 30, 2026
Share count, 1 year
+2.3%
2025-10-23 to 2026-10-22 · +5.1% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$2.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$61.9M cash; operating cash flow -$34.8M a quarter.Report 2026-09-30
Shares outstanding60,469,687 (2026-10-22); 59,096,630 a year earlier; 57,531,999 three years earlier.Cover page 2026-10-22
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Washington, District of Columbia, United StatesPCAOB Form AP 2026-02-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$69.8M-$22.6M-$28.4M$61.9MNo debt tags$229.3M10-Q 2026-10-29
Q2 2026
2026-06-30
$50.5M-$62.5M-$31.1M$55.9MNo debt tags$215.7M10-Q 2026-08-06
Q1 2026
2026-03-31
$51.7M-$48.6M-$50.2M$54.0MNo debt tags$217.8M10-Q 2026-05-07
Q4 2025
2025-12-31
$57.2M-$141.2M-$29.4M$84.9MNo debt tags$216.1M10-K 2026-02-12
Q3 2025
2025-09-30
$56.3M-$22.6M-$31.6M$70.0MNo debt tags$212.1M10-Q 2026-10-29
Q2 2025
2025-06-30
$52.6M-$27.2M-$15.3M$81.0MNo debt tags$203.5M10-Q 2026-08-06
Q1 2025
2025-03-31
$50.0M-$29.5M-$33.1M$111.8MNo debt tags$201.4M10-Q 2026-05-07
Q4 2024
2024-12-31
$53.2M-$4.9M-$1.8M$102.3MNo debt tags$198.8M10-K 2026-02-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-02-12
Latest annual report10-K2026-02-12
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-10-28
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.5%
1 month-7.2%
3 months-20.7%
Year to date-54.8%
1 year-8.1%
From 52-week high-58.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
IMRXImmuneering Corporation$3.52-5.12%$228.0M
AMRNAmarin Corporation plc$11.31-0.62%$233.4M
BCYCBicycle Therapeutics plc$3.18-5.64%$222.9M
DRUGBright Minds Biosciences Inc.$22.61-2.16%$222.0M
ARCTArcturus Therapeutics Holdings Inc.$8.31-0.60%$239.5M
FTHFaeth Therapeutics Inc.$9.28-7.48%$239.8M
BIOABioAge Labs Inc.$5.22-5.95%$239.9M
RCKTRocket Pharmaceuticals Inc.$2.16-6.09%$241.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier